EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany

Christoph Bidlingmaier, Christine Heller, Florian Langer, Wolfgang Miesbach, Ute Scholz, Johannes Oldenburg, Eveline Nüesch, Helena Palmborg, Elena Santagostino, Andreas Tiede

Research and Practice in Thrombosis and Haemostasis · 2024-07 · 8 (5) · 102482

DOI: 10.1016/j.rpth.2024.102482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2024-07. Verfasst von Christoph Bidlingmaier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Dr. von Hauner Children's Hospital, Pediatric Hemophilia Center, LMU Munich, Munich, Germany. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sobi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world experience with efmoroctocog alfa (a recombinant factor [F]VIII Fc fusion protein [rFVIIIFc]) and eftrenonacog alfa (a recombinant factor IX Fc fusion protein [rFIXFc]) is needed to bridge evidence gaps.

Objectives

To describe rFVIIIFc/rFIXFc usage and effectiveness over a 24-month prospective period.

Methods

PREVENT (NCT03055611), a noninterventional study across 25 German hemophilia treatment centers, enrolled previously treated persons with hemophilia A and B (all ages/severities) on individualized rFVIIIFc/rFIXFc prophylaxis before/at enrollment. Primary endpoints included annualized bleeding rate (ABR), injection frequency (IF), and factor consumption (FC). Additionally, up to 12 months of retrospective FVIII/FIX data were collected. Physician and patient satisfaction, and safety outcomes were also assessed.

Results

Overall, 150 patients received ≥1 rFVIIIFc dose and 47 patients received ≥1 rFIXFc dose, with median prospective follow-up of 20.6 and 21.0 months, respectively. rFVIIIFc/rFIXFc demonstrated low median ABR (0.5/1.7), annualized IF (121.8/52.2 injections/y), and FC (4611.7/2423.9 IU/kg) in line with product labels. Compared with previous FVIII/FIX, there was a 56.0% reduction in ABR for rFVIIIFc (rate ratio, 0.44; 95% CI, 0.31-0.64), with no change for rFIXFc (rate ratio, 0.93; 95% CI, 0.66-1.31); rFVIIIFc/rFIXFc reduced annualized IF (rFVIIIFc, mean difference, -31.7; 95% CI, -40.3 to -23.1; rFIXFc, mean difference, -37.3; 95% CI, -46.9 to -27.8), while FC remained stable (rFVIIIFc, +374.1; 95% CI, +46.8 to +701.3; rFIXFc, +503.9; 95% CI, +95.4 to +912.4). Most physicians and patients were satisfied or highly satisfied with rFVIIIFc/rFIXFc. rFVIIIFc/rFIXFc were well tolerated, with no inhibitor development or treatment-related serious adverse events.

Conclusion

Real-world PREVENT data complement phase 3 trials and show that individualized rFVIIIFc/rFIXFc prophylaxis provided stable bleed protection with low IF and maintained FC. Compared with previous FVIII, ABR was considerably reduced with rFVIIIFc, with stable annualized FC. For rFIXFc, bleed protection was maintained vs previous FIX while reducing annualized IF.

Schlagwörter

Stichwörter der Autor:innen

hemophilia Ahemophilia BrFIXFcrFVIIIFcrecombinant fusion protein

Autor:innen und Institutionen

  • Department of Pediatrics, Dr. von Hauner Children's Hospital, Pediatric Hemophilia Center, LMU Munich, Munich, Germany.
  • Department of Pediatric Haemostaseology, University Hospital of Frankfurt, Frankfurt, Germany.
  • University Medical Centre Hamburg-Eppendorf, II. Medical Clinic and Polyclinic, Hamburg, Germany.
  • University Hospital, Frankfurt Medical Clinic II, Frankfurt, Germany.
  • Center of Coagulation Disorders, Leipzig, Germany.
  • University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany.

Förderung

  • Sobi

Zitieren

APA

Bidlingmaier, C., Heller, C., Langer, F., Miesbach, W., Scholz, U., Oldenburg, J., Nüesch, E., Palmborg, H., Santagostino, E., & Tiede, A. (2024). Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany. Research and Practice in Thrombosis and Haemostasis, 8(5), 102482. https://doi.org/10.1016/j.rpth.2024.102482

Vancouver

Bidlingmaier C, Heller C, Langer F, Miesbach W, Scholz U, Oldenburg J, et al. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany. Research and Practice in Thrombosis and Haemostasis. 2024;8(5):102482. doi:10.1016/j.rpth.2024.102482

BibTeX
@article{Bidlingmaier2024,
  author = {Bidlingmaier, Christoph and Heller, Christine and Langer, Florian and Miesbach, Wolfgang and Scholz, Ute and Oldenburg, Johannes and Nüesch, Eveline and Palmborg, Helena and Santagostino, Elena and Tiede, Andreas},
  title = {Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  year = {2024},
  volume = {8},
  number = {5},
  pages = {102482},
  doi = {10.1016/j.rpth.2024.102482}
}
Kostenlos starten →